MedTrace Logo

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

NCT00346385 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2015-03-26

No results posted yet for this study

Summary

RATIONALE: Monoclonal antibodies, such as BB-10901, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

PURPOSE: This phase I trial is studying the side effects and best dose of BB-10901 in treating patients with relapsed or refractory solid tumors.

Conditions

Interventions

DRUG

BB-10901

dose escalation study, dose will vary per cohort. patients will receive an IV infusion once every three weeks.

Sponsors & Collaborators

  • ImmunoGen, Inc.

    lead INDUSTRY

Principal Investigators

  • Paul C. Lorigan, MD · The Christie NHS Foundation Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00346385 on ClinicalTrials.gov